{"name":"LEO Pharma","slug":"leo-pharma","ticker":"","exchange":"","domain":"","description":"LEO Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen The company is 100% integrated into a private foundation owned by the LEO Foundation. LEO Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation. In 1945, it was the first producer of penicillin outside the US and UK.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1995-01-01","label":"Azelex first approved","drug":"Azelex","drugSlug":"azelaic-acid","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Adbry first approved","drug":"Adbry","drugSlug":"tralokinumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-18","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-18","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-01","label":"Cromoglicate Phase 3 readout (Burn Scar, Itch Scarring)","drug":"Cromoglicate","drugSlug":"cromoglicate","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-12-08","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-28","label":"Azelex patent expiry (Method of Use)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":30,"colorKey":"immunology","drugs":[{"name":"Betamethasone dipropionate aerosol spray","genericName":"Betamethasone dipropionate aerosol spray","slug":"betamethasone-dipropionate-aerosol-spray","indication":"Severe skin conditions such as psoriasis, atopic dermatitis, and seborrheic dermatitis","status":"phase_2"},{"name":"Betamethasone dipropionate cream","genericName":"Betamethasone dipropionate cream","slug":"betamethasone-dipropionate-cream","indication":"Seborrheic dermatitis","status":"phase_2"},{"name":"Betamethasone plus calcipotriol","genericName":"Betamethasone plus calcipotriol","slug":"betamethasone-plus-calcipotriol","indication":"Psoriasis","status":"phase_2"},{"name":"Betamethasone-17,21-dipropionate","genericName":"Betamethasone-17,21-dipropionate","slug":"betamethasone-17-21-dipropionate","indication":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids","status":"phase_3"},{"name":"Betnovat® ointment","genericName":"Betnovat® ointment","slug":"betnovat-ointment","indication":"Severe skin conditions such as eczema, psoriasis, and dermatitis","status":"phase_2"},{"name":"Calcipotriene plus betamethasone dipropionate ointment","genericName":"Calcipotriene plus betamethasone dipropionate ointment","slug":"calcipotriene-plus-betamethasone-dipropionate-ointment","indication":"Moderate to severe plaque psoriasis","status":"phase_2"},{"name":"Calcipotriene/betamethasone gel and ointment","genericName":"Calcipotriene/betamethasone gel and ointment","slug":"calcipotriene-betamethasone-gel-and-ointment","indication":"Plaque psoriasis","status":"phase_3"},{"name":"Calcipotriol BDP gel","genericName":"Calcipotriol BDP gel","slug":"calcipotriol-bdp-gel","indication":"Plaque psoriasis (topical treatment)","status":"phase_3"},{"name":"Calcipotriol plus betamethasone","genericName":"Calcipotriol plus betamethasone","slug":"calcipotriol-plus-betamethasone","indication":"Plaque psoriasis","status":"phase_3"},{"name":"Calcipotriol plus hydrocortisone ointment","genericName":"Calcipotriol plus hydrocortisone ointment","slug":"calcipotriol-plus-hydrocortisone-ointment","indication":"Psoriasis (plaque psoriasis)","status":"phase_3"},{"name":"Calcipotriol plus hydrocortisone ointment vehicle","genericName":"Calcipotriol plus hydrocortisone ointment vehicle","slug":"calcipotriol-plus-hydrocortisone-ointment-vehicle","indication":"Plaque psoriasis","status":"phase_3"},{"name":"Calcipotriol scalp solution","genericName":"Calcipotriol scalp solution","slug":"calcipotriol-scalp-solution","indication":"Psoriasis of the scalp","status":"phase_3"},{"name":"Clobetasol propionate cream","genericName":"Clobetasol propionate cream","slug":"clobetasol-propionate-cream","indication":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","status":"marketed"},{"name":"Daivobet® gel","genericName":"Daivobet® gel","slug":"daivobet-gel","indication":"Plaque psoriasis (topical treatment)","status":"phase_3"},{"name":"Daivonex® scalp solution","genericName":"Daivonex® scalp solution","slug":"daivonex-scalp-solution","indication":"Psoriasis of the scalp","status":"marketed"},{"name":"Dermovat ointment","genericName":"Dermovat ointment","slug":"dermovat-ointment","indication":"Inflammatory and pruritic dermatological conditions (e.g., psoriasis, eczema, lichen planus)","status":"phase_2"},{"name":"Diclofenac sodium gel 3%","genericName":"Diclofenac sodium gel 3%","slug":"diclofenac-sodium-gel-3","indication":"Topical treatment of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"marketed"},{"name":"Diprosone® ointment","genericName":"Diprosone® ointment","slug":"diprosone-ointment","indication":"Atopic dermatitis","status":"phase_2"},{"name":"Dovobet® ointment","genericName":"Dovobet® ointment","slug":"dovobet-ointment","indication":"Plaque psoriasis (topical treatment)","status":"phase_3"},{"name":"Dovonex® = calcipotriol","genericName":"Dovonex® = calcipotriol","slug":"dovonex-calcipotriol","indication":"Plaque psoriasis","status":"phase_3"},{"name":"Dovonex® cream","genericName":"Dovonex® cream","slug":"dovonex-cream","indication":"Psoriasis","status":"phase_2"},{"name":"LEO 80190","genericName":"LEO 80190","slug":"leo-80190","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LEO 90100","genericName":"LEO 90100","slug":"leo-90100","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LEO 90100 foam","genericName":"LEO 90100 foam","slug":"leo-90100-foam","indication":"Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis)","status":"phase_3"},{"name":"LEO 90105 = calcipotriol + betamethasone dipropionate","genericName":"LEO 90105 = calcipotriol + betamethasone dipropionate","slug":"leo-90105-calcipotriol-betamethasone-dipropionate","indication":"Plaque psoriasis (topical treatment)","status":"phase_3"},{"name":"LEO43204 gel","genericName":"LEO43204 gel","slug":"leo43204-gel","indication":"Psoriasis","status":"phase_3"},{"name":"Rinderon® - DP = betamethasone dipropionate","genericName":"Rinderon® - DP = betamethasone dipropionate","slug":"rinderon-dp-betamethasone-dipropionate","indication":"Severe skin conditions such as psoriasis, eczema, and dermatitis","status":"phase_3"},{"name":"Tacalcitol ointment","genericName":"Tacalcitol ointment","slug":"tacalcitol-ointment","indication":"Treatment of psoriasis","status":"phase_3"},{"name":"Vehicle gel (SH H 655 PBA)","genericName":"Vehicle gel (SH H 655 PBA)","slug":"vehicle-gel-sh-h-655-pba","indication":"Atopic dermatitis","status":"phase_3"},{"name":"Xamiol® Gel","genericName":"Xamiol® Gel","slug":"xamiol-gel","indication":"Plaque psoriasis (topical treatment)","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"Adbry","genericName":"TRALOKINUMAB","slug":"tralokinumab","indication":"Moderate to severe atopic dermatitis","status":"marketed"},{"name":"Aerosol foam vehicle","genericName":"Aerosol foam vehicle","slug":"aerosol-foam-vehicle","indication":"Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulated with this vehicle)","status":"phase_3"},{"name":"Any topical drug treatment","genericName":"Any topical drug treatment","slug":"any-topical-drug-treatment","indication":"Atopic dermatitis","status":"phase_2"},{"name":"Azelaic Acid Cream","genericName":"Azelaic Acid Cream","slug":"azelaic-acid-cream","indication":"Rosacea","status":"marketed"},{"name":"Azelex","genericName":"AZELAIC ACID","slug":"azelaic-acid","indication":"Acne vulgaris","status":"marketed"},{"name":"Delgocitinib cream","genericName":"Delgocitinib cream","slug":"delgocitinib-cream","indication":"Atopic dermatitis (topical cream formulation)","status":"phase_3"},{"name":"LEO 43204 gel","genericName":"LEO 43204 gel","slug":"leo-43204-gel","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LEO 80185 gel","genericName":"LEO 80185 gel","slug":"leo-80185-gel","indication":"Atopic dermatitis","status":"phase_3"},{"name":"LEO 80185 vehicle","genericName":"LEO 80185 vehicle","slug":"leo-80185-vehicle","indication":"Dermatological conditions (specific indication unknown)","status":"phase_3"},{"name":"LEO 80190 Vehicle","genericName":"LEO 80190 Vehicle","slug":"leo-80190-vehicle","indication":"Dermatological conditions (specific indication dependent on active ingredient combined with vehicle)","status":"phase_3"},{"name":"LEO 90100 aerosol foam","genericName":"LEO 90100 aerosol foam","slug":"leo-90100-aerosol-foam","indication":"Inflammatory skin conditions (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"LEO 90100 aerosol foam vehicle","genericName":"LEO 90100 aerosol foam vehicle","slug":"leo-90100-aerosol-foam-vehicle","indication":"Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulation)","status":"phase_3"},{"name":"Petrolatum ointment","genericName":"Petrolatum ointment","slug":"petrolatum-ointment","indication":"Dry skin and xerosis","status":"marketed"},{"name":"Placebo + TCS","genericName":"Placebo + TCS","slug":"placebo-tcs","indication":"Control arm in phase 3 dermatological trials (specific indication unknown)","status":"phase_3"},{"name":"Topical suspension vehicle","genericName":"Topical suspension vehicle","slug":"topical-suspension-vehicle","indication":"Vehicle/excipient for topical dermatological formulations","status":"marketed"},{"name":"Tralokinumab + TCS","genericName":"Tralokinumab + TCS","slug":"tralokinumab-tcs","indication":"Moderate to severe atopic dermatitis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"cardiovascular","drugs":[{"name":"Brimonidine Tartrate Gel","genericName":"Brimonidine Tartrate Gel","slug":"brimonidine-tartrate-gel","indication":"Treatment of erythema associated with rosacea","status":"phase_2"},{"name":"Calcipotriol plus betamethasone dipropionate ointment","genericName":"Calcipotriol plus betamethasone dipropionate ointment","slug":"calcipotriol-plus-betamethasone-dipropionate-ointment","indication":"Other","status":"marketed"},{"name":"Diprosalic ointment","genericName":"Diprosalic ointment","slug":"diprosalic-ointment","indication":"Other","status":"phase_2"},{"name":"Doxycycline (Oracea)","genericName":"Doxycycline (Oracea)","slug":"doxycycline-oracea","indication":"Rosacea (inflammatory lesions)","status":"marketed"},{"name":"Elidel®","genericName":"Elidel®","slug":"elidel","indication":"Other","status":"marketed"},{"name":"Inactive 15% gel base","genericName":"Inactive 15% gel base","slug":"inactive-15-gel-base","indication":"Other","status":"phase_2"},{"name":"Ingenol Mebutate Gel, 0.015%","genericName":"Ingenol Mebutate Gel, 0.015%","slug":"ingenol-mebutate-gel-0-015","indication":"Other","status":"marketed"},{"name":"Ingenol mebutate gel 0.05 %","genericName":"Ingenol mebutate gel 0.05 %","slug":"ingenol-mebutate-gel-0-05","indication":"Actinic keratosis (field treatment)","status":"phase_3"},{"name":"Ingenol metabute","genericName":"Ingenol metabute","slug":"ingenol-metabute","indication":"Actinic keratosis (field treatment on face or scalp)","status":"phase_3"},{"name":"LEO 29102 Plus Betamethasone Dipropionate","genericName":"LEO 29102 Plus Betamethasone Dipropionate","slug":"leo-29102-plus-betamethasone-dipropionate","indication":"Other","status":"phase_2"},{"name":"LEO 29102 Plus Calcipotriol Cream","genericName":"LEO 29102 Plus Calcipotriol Cream","slug":"leo-29102-plus-calcipotriol-cream","indication":"Other","status":"phase_2"},{"name":"Leukotriene B4","genericName":"Leukotriene B4","slug":"leukotriene-b4","indication":"Other","status":"phase_1"},{"name":"Locoid","genericName":"Locoid","slug":"locoid","indication":"Other","status":"phase_1"},{"name":"Picato","genericName":"Picato","slug":"picato","indication":"Actinic keratosis","status":"discontinued"},{"name":"Pimecrolimus cream","genericName":"Pimecrolimus cream","slug":"pimecrolimus-cream","indication":"Other","status":"marketed"},{"name":"Toctino","genericName":"Toctino","slug":"toctino","indication":"Other","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Cromoglicate","genericName":"Cromoglicate","slug":"cromoglicate","indication":"Allergic Keratoconjunctivitis","status":"discontinued"},{"name":"LP0113 aerosol spray","genericName":"LP0113 aerosol spray","slug":"lp0113-aerosol-spray","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Fucidin® cream","genericName":"Fucidin® cream","slug":"fucidin-cream","indication":"Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis)","status":"marketed"},{"name":"Metronidazole (Metrogel)","genericName":"Metronidazole (Metrogel)","slug":"metronidazole-metrogel","indication":"Rosacea (topical gel formulation)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"innohep®","genericName":"innohep®","slug":"innohep","indication":"Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery","status":"marketed"}]}],"pipeline":[{"name":"Adbry","genericName":"TRALOKINUMAB","slug":"tralokinumab","phase":"marketed","mechanism":"Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"Aerosol foam vehicle","genericName":"Aerosol foam vehicle","slug":"aerosol-foam-vehicle","phase":"phase_3","mechanism":"An aerosol foam vehicle formulation designed to deliver active pharmaceutical ingredients topically to affected skin areas with improved coverage and adherence.","indications":["Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulated with this vehicle)"],"catalyst":""},{"name":"Any topical drug treatment","genericName":"Any topical drug treatment","slug":"any-topical-drug-treatment","phase":"phase_2","mechanism":"Calcineurin inhibitor","indications":["Atopic dermatitis"],"catalyst":""},{"name":"Azelaic Acid Cream","genericName":"Azelaic Acid Cream","slug":"azelaic-acid-cream","phase":"marketed","mechanism":"Azelaic acid reduces bacterial colonization and normalizes keratinization to treat inflammatory skin conditions.","indications":["Rosacea","Acne vulgaris","Post-inflammatory hyperpigmentation"],"catalyst":""},{"name":"Azelex","genericName":"AZELAIC ACID","slug":"azelaic-acid","phase":"marketed","mechanism":"Azelex works by inhibiting the enzyme 3-oxo-5-alpha-steroid 4-dehydrogenase 2, which is involved in the production of androgens that contribute to acne and rosacea.","indications":["Acne vulgaris","Rosacea"],"catalyst":""},{"name":"Betamethasone dipropionate aerosol spray","genericName":"Betamethasone dipropionate aerosol spray","slug":"betamethasone-dipropionate-aerosol-spray","phase":"phase_2","mechanism":"Betamethasone dipropionate aerosol spray is a topical corticosteroid that reduces inflammation and suppresses the immune system.","indications":["Severe skin conditions such as psoriasis, atopic dermatitis, and seborrheic dermatitis"],"catalyst":""},{"name":"Betamethasone dipropionate cream","genericName":"Betamethasone dipropionate cream","slug":"betamethasone-dipropionate-cream","phase":"phase_2","mechanism":"Betamethasone dipropionate cream is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system.","indications":["Seborrheic dermatitis","Psoriasis"],"catalyst":""},{"name":"Betamethasone plus calcipotriol","genericName":"Betamethasone plus calcipotriol","slug":"betamethasone-plus-calcipotriol","phase":"phase_2","mechanism":"Betamethasone is a glucocorticoid receptor agonist, while calcipotriol is a vitamin D3 analog that acts as a retinoid X receptor agonist.","indications":["Psoriasis"],"catalyst":""},{"name":"Betamethasone-17,21-dipropionate","genericName":"Betamethasone-17,21-dipropionate","slug":"betamethasone-17-21-dipropionate","phase":"phase_3","mechanism":"Betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.","indications":["Inflammatory and pruritic dermatoses responsive to topical corticosteroids","Eczema, psoriasis, and other chronic inflammatory skin conditions"],"catalyst":""},{"name":"Betnovat® ointment","genericName":"Betnovat® ointment","slug":"betnovat-ointment","phase":"phase_2","mechanism":"Betnovat ointment is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system.","indications":["Severe skin conditions such as eczema, psoriasis, and dermatitis"],"catalyst":""},{"name":"Brimonidine Tartrate Gel","genericName":"Brimonidine Tartrate Gel","slug":"brimonidine-tartrate-gel","phase":"phase_2","mechanism":"Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin.","indications":["Treatment of erythema associated with rosacea"],"catalyst":""},{"name":"Calcipotriene plus betamethasone dipropionate ointment","genericName":"Calcipotriene plus betamethasone dipropionate ointment","slug":"calcipotriene-plus-betamethasone-dipropionate-ointment","phase":"phase_2","mechanism":"Calcipotriene plus betamethasone dipropionate ointment works by reducing inflammation and slowing the growth of skin cells in the treatment of psoriasis.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Calcipotriene/betamethasone gel and ointment","genericName":"Calcipotriene/betamethasone gel and ointment","slug":"calcipotriene-betamethasone-gel-and-ointment","phase":"phase_3","mechanism":"Calcipotriene (a vitamin D analog) reduces skin cell proliferation and promotes differentiation, while betamethasone (a corticosteroid) suppresses inflammation and immune response in psoriatic skin.","indications":["Plaque psoriasis","Psoriatic dermatitis"],"catalyst":""},{"name":"Calcipotriol BDP gel","genericName":"Calcipotriol BDP gel","slug":"calcipotriol-bdp-gel","phase":"phase_3","mechanism":"Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and reduce inflammation in psoriasis.","indications":["Plaque psoriasis (topical treatment)"],"catalyst":""},{"name":"Calcipotriol plus betamethasone","genericName":"Calcipotriol plus betamethasone","slug":"calcipotriol-plus-betamethasone","phase":"phase_3","mechanism":"Calcipotriol (a vitamin D analogue) and betamethasone (a corticosteroid) work together to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.","indications":["Plaque psoriasis","Psoriasis vulgaris"],"catalyst":""},{"name":"Calcipotriol plus betamethasone dipropionate ointment","genericName":"Calcipotriol plus betamethasone dipropionate ointment","slug":"calcipotriol-plus-betamethasone-dipropionate-ointment","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calcipotriol plus hydrocortisone ointment","genericName":"Calcipotriol plus hydrocortisone ointment","slug":"calcipotriol-plus-hydrocortisone-ointment","phase":"phase_3","mechanism":"Calcipotriol (a vitamin D analogue) reduces skin cell proliferation and promotes differentiation, while hydrocortisone (a corticosteroid) suppresses inflammation and immune responses in the skin.","indications":["Psoriasis (plaque psoriasis)","Atopic dermatitis"],"catalyst":""},{"name":"Calcipotriol plus hydrocortisone ointment vehicle","genericName":"Calcipotriol plus hydrocortisone ointment vehicle","slug":"calcipotriol-plus-hydrocortisone-ointment-vehicle","phase":"phase_3","mechanism":"Calcipotriol (a vitamin D analogue) reduces keratinocyte proliferation and promotes differentiation, while hydrocortisone provides anti-inflammatory effects to treat psoriasis.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"Calcipotriol scalp solution","genericName":"Calcipotriol scalp solution","slug":"calcipotriol-scalp-solution","phase":"phase_3","mechanism":"Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell proliferation and differentiation, reducing psoriatic plaques.","indications":["Psoriasis of the scalp"],"catalyst":""},{"name":"Clobetasol propionate cream","genericName":"Clobetasol propionate cream","slug":"clobetasol-propionate-cream","phase":"marketed","mechanism":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","indications":["Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","Psoriasis","Lichen planus","Eczema","Dermatitis"],"catalyst":""},{"name":"Cromoglicate","genericName":"Cromoglicate","slug":"cromoglicate","phase":"discontinued","mechanism":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","indications":["Allergic Keratoconjunctivitis","Allergic conjunctivitis","Allergic rhinitis","Asthma","Asthma management"],"catalyst":""},{"name":"Daivobet® gel","genericName":"Daivobet® gel","slug":"daivobet-gel","phase":"phase_3","mechanism":"Daivobet combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.","indications":["Plaque psoriasis (topical treatment)"],"catalyst":""},{"name":"Daivonex® scalp solution","genericName":"Daivonex® scalp solution","slug":"daivonex-scalp-solution","phase":"marketed","mechanism":"Daivonex scalp solution is a vitamin D3 analogue that binds to vitamin D receptors on skin cells to reduce excessive cell proliferation and inflammation characteristic of psoriasis.","indications":["Psoriasis of the scalp"],"catalyst":""},{"name":"Delgocitinib cream","genericName":"Delgocitinib cream","slug":"delgocitinib-cream","phase":"phase_3","mechanism":"Delgocitinib is a JAK inhibitor that suppresses inflammatory cytokine signaling in immune cells to reduce skin inflammation and itching in atopic dermatitis.","indications":["Atopic dermatitis (topical cream formulation)"],"catalyst":""},{"name":"Dermovat ointment","genericName":"Dermovat ointment","slug":"dermovat-ointment","phase":"phase_2","mechanism":"Dermovat ointment is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.","indications":["Inflammatory and pruritic dermatological conditions (e.g., psoriasis, eczema, lichen planus)"],"catalyst":""},{"name":"Diclofenac sodium gel 3%","genericName":"Diclofenac sodium gel 3%","slug":"diclofenac-sodium-gel-3","phase":"marketed","mechanism":"Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.","indications":["Topical treatment of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","Acute pain and inflammation from minor injuries and sprains"],"catalyst":""},{"name":"Diprosalic ointment","genericName":"Diprosalic ointment","slug":"diprosalic-ointment","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Diprosone® ointment","genericName":"Diprosone® ointment","slug":"diprosone-ointment","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Atopic dermatitis","Psoriasis","Seborrhoeic dermatitis"],"catalyst":""},{"name":"Dovobet® ointment","genericName":"Dovobet® ointment","slug":"dovobet-ointment","phase":"phase_3","mechanism":"Dovobet combines calcipotriene (a vitamin D analogue) and betamethasone dipropionate (a corticosteroid) to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.","indications":["Plaque psoriasis (topical treatment)"],"catalyst":""},{"name":"Dovonex® = calcipotriol","genericName":"Dovonex® = calcipotriol","slug":"dovonex-calcipotriol","phase":"phase_3","mechanism":"Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell proliferation and differentiation, reducing excessive keratinocyte growth.","indications":["Plaque psoriasis","Psoriatic dermatitis"],"catalyst":""},{"name":"Dovonex® cream","genericName":"Dovonex® cream","slug":"dovonex-cream","phase":"phase_2","mechanism":"Calcitriol binds to vitamin D receptors (VDRs) on keratinocytes, promoting differentiation and reducing inflammation.","indications":["Psoriasis"],"catalyst":""},{"name":"Doxycycline (Oracea)","genericName":"Doxycycline (Oracea)","slug":"doxycycline-oracea","phase":"marketed","mechanism":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and at sub-antimicrobial doses in Oracea formulation, it reduces matrix metalloproteinase activity to decrease inflammation.","indications":["Rosacea (inflammatory lesions)"],"catalyst":""},{"name":"Elidel®","genericName":"Elidel®","slug":"elidel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fucidin® cream","genericName":"Fucidin® cream","slug":"fucidin-cream","phase":"marketed","mechanism":"Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth.","indications":["Bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected wounds, folliculitis)","Staphylococcus aureus skin infections including MRSA"],"catalyst":""},{"name":"Inactive 15% gel base","genericName":"Inactive 15% gel base","slug":"inactive-15-gel-base","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ingenol Mebutate Gel, 0.015%","genericName":"Ingenol Mebutate Gel, 0.015%","slug":"ingenol-mebutate-gel-0-015","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ingenol mebutate gel 0.05 %","genericName":"Ingenol mebutate gel 0.05 %","slug":"ingenol-mebutate-gel-0-05","phase":"phase_3","mechanism":"Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and promote immune-mediated clearance of damaged skin.","indications":["Actinic keratosis (field treatment)"],"catalyst":""},{"name":"Ingenol metabute","genericName":"Ingenol metabute","slug":"ingenol-metabute","phase":"phase_3","mechanism":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of treated lesions.","indications":["Actinic keratosis (field treatment on face or scalp)"],"catalyst":""},{"name":"LEO 29102 Plus Betamethasone Dipropionate","genericName":"LEO 29102 Plus Betamethasone Dipropionate","slug":"leo-29102-plus-betamethasone-dipropionate","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LEO 29102 Plus Calcipotriol Cream","genericName":"LEO 29102 Plus Calcipotriol Cream","slug":"leo-29102-plus-calcipotriol-cream","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LEO 43204 gel","genericName":"LEO 43204 gel","slug":"leo-43204-gel","phase":"phase_3","mechanism":"LEO 43204 is a topical calcineurin inhibitor that suppresses local immune responses in the skin.","indications":["Atopic dermatitis","Eczema"],"catalyst":""},{"name":"LEO 80185 gel","genericName":"LEO 80185 gel","slug":"leo-80185-gel","phase":"phase_3","mechanism":"LEO 80185 is a topical calcineurin inhibitor that suppresses local immune responses in the skin.","indications":["Atopic dermatitis","Eczema"],"catalyst":""},{"name":"LEO 80185 vehicle","genericName":"LEO 80185 vehicle","slug":"leo-80185-vehicle","phase":"phase_3","mechanism":"LEO 80185 vehicle is a topical formulation designed to deliver active pharmaceutical ingredients to the skin.","indications":["Dermatological conditions (specific indication unknown)"],"catalyst":""},{"name":"LEO 80190","genericName":"LEO 80190","slug":"leo-80190","phase":"phase_3","mechanism":"LEO 80190 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LEO 80190 Vehicle","genericName":"LEO 80190 Vehicle","slug":"leo-80190-vehicle","phase":"phase_3","mechanism":"LEO 80190 Vehicle is a topical formulation vehicle designed to enhance dermal delivery of active pharmaceutical ingredients.","indications":["Dermatological conditions (specific indication dependent on active ingredient combined with vehicle)"],"catalyst":""},{"name":"LEO 90100","genericName":"LEO 90100","slug":"leo-90100","phase":"phase_3","mechanism":"LEO 90100 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"LEO 90100 aerosol foam","genericName":"LEO 90100 aerosol foam","slug":"leo-90100-aerosol-foam","phase":"phase_3","mechanism":"LEO 90100 is a topical corticosteroid aerosol foam formulation designed for enhanced skin penetration and coverage in inflammatory skin conditions.","indications":["Inflammatory skin conditions (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"LEO 90100 aerosol foam vehicle","genericName":"LEO 90100 aerosol foam vehicle","slug":"leo-90100-aerosol-foam-vehicle","phase":"phase_3","mechanism":"LEO 90100 is a topical aerosol foam vehicle designed to deliver active pharmaceutical ingredients to the skin with improved penetration and patient convenience.","indications":["Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulation)"],"catalyst":""},{"name":"LEO 90100 foam","genericName":"LEO 90100 foam","slug":"leo-90100-foam","phase":"phase_3","mechanism":"LEO 90100 foam is a topical corticosteroid formulation designed for enhanced skin penetration and anti-inflammatory effects in dermatological conditions.","indications":["Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis)"],"catalyst":""},{"name":"LEO 90105 = calcipotriol + betamethasone dipropionate","genericName":"LEO 90105 = calcipotriol + betamethasone dipropionate","slug":"leo-90105-calcipotriol-betamethasone-dipropionate","phase":"phase_3","mechanism":"LEO 90105 combines a vitamin D analog (calcipotriol) that regulates skin cell differentiation with a potent topical corticosteroid (betamethasone dipropionate) to reduce inflammation and abnormal keratinocyte proliferation in psoriasis.","indications":["Plaque psoriasis (topical treatment)"],"catalyst":""},{"name":"LEO43204 gel","genericName":"LEO43204 gel","slug":"leo43204-gel","phase":"phase_3","mechanism":"LEO43204 is a topical retinoid that modulates retinoid receptor signaling to reduce inflammation and promote skin cell differentiation in dermatological conditions.","indications":["Psoriasis","Other inflammatory skin conditions"],"catalyst":""},{"name":"LP0113 aerosol spray","genericName":"LP0113 aerosol spray","slug":"lp0113-aerosol-spray","phase":"phase_2","mechanism":"LP0113 aerosol spray is a corticosteroid used to reduce inflammation in the lungs.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Leukotriene B4","genericName":"Leukotriene B4","slug":"leukotriene-b4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Locoid","genericName":"Locoid","slug":"locoid","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Metronidazole (Metrogel)","genericName":"Metronidazole (Metrogel)","slug":"metronidazole-metrogel","phase":"marketed","mechanism":"Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species, leading to cell death.","indications":["Rosacea (topical gel formulation)","Bacterial vaginosis","Trichomoniasis","Anaerobic bacterial infections","Amebiasis"],"catalyst":""},{"name":"Petrolatum ointment","genericName":"Petrolatum ointment","slug":"petrolatum-ointment","phase":"marketed","mechanism":"Petrolatum ointment forms an occlusive barrier on the skin surface to prevent water loss and protect against irritants.","indications":["Dry skin and xerosis","Minor skin irritation and chafing","Wound care and skin protection","General skin moisturization"],"catalyst":""},{"name":"Picato","genericName":"Picato","slug":"picato","phase":"discontinued","mechanism":"Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type","indications":["Actinic keratosis"],"catalyst":""},{"name":"Pimecrolimus cream","genericName":"Pimecrolimus cream","slug":"pimecrolimus-cream","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo + TCS","genericName":"Placebo + TCS","slug":"placebo-tcs","phase":"phase_3","mechanism":"This is a control arm combining placebo with topical corticosteroid (TCS) therapy, used as a comparator in clinical trials to establish efficacy of an investigational treatment.","indications":["Control arm in phase 3 dermatological trials (specific indication unknown)"],"catalyst":""},{"name":"Rinderon® - DP = betamethasone dipropionate","genericName":"Rinderon® - DP = betamethasone dipropionate","slug":"rinderon-dp-betamethasone-dipropionate","phase":"phase_3","mechanism":"Rinderon inhibits the body's inflammatory response by suppressing the production of various pro-inflammatory cytokines.","indications":["Severe skin conditions such as psoriasis, eczema, and dermatitis"],"catalyst":""},{"name":"Tacalcitol ointment","genericName":"Tacalcitol ointment","slug":"tacalcitol-ointment","phase":"phase_3","mechanism":"Tacalcitol ointment is a synthetic vitamin D3 analog that modulates the vitamin D receptor.","indications":["Treatment of psoriasis"],"catalyst":""},{"name":"Toctino","genericName":"Toctino","slug":"toctino","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical suspension vehicle","genericName":"Topical suspension vehicle","slug":"topical-suspension-vehicle","phase":"marketed","mechanism":"A topical suspension vehicle is a pharmaceutical formulation designed to deliver active ingredients to the skin surface through a liquid suspension base.","indications":["Vehicle/excipient for topical dermatological formulations"],"catalyst":""},{"name":"Tralokinumab + TCS","genericName":"Tralokinumab + TCS","slug":"tralokinumab-tcs","phase":"phase_3","mechanism":"Tralokinumab is an IL-13 inhibitor, and when combined with topical corticosteroids (TCS), it targets the underlying inflammatory pathways in atopic dermatitis.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"Vehicle gel (SH H 655 PBA)","genericName":"Vehicle gel (SH H 655 PBA)","slug":"vehicle-gel-sh-h-655-pba","phase":"phase_3","mechanism":"Vehicle gel is a topical formulation used to deliver active pharmaceutical ingredients to the skin.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""},{"name":"Xamiol® Gel","genericName":"Xamiol® Gel","slug":"xamiol-gel","phase":"marketed","mechanism":"Xamiol® Gel combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.","indications":["Plaque psoriasis (topical treatment)"],"catalyst":""},{"name":"innohep®","genericName":"innohep®","slug":"innohep","phase":"marketed","mechanism":"Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","indications":["Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery","Treatment of acute deep vein thrombosis and pulmonary embolism","Prophylaxis of thromboembolism in patients with acute myocardial infarction"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPakphUHpyQzZLQlpoWnFsVU81RTBxeklxTlFNQWd2UktYbWowc01mMFcwNmtsVFZ3QmdEVldPWVJCZ1owVUx2ZXItc0ZLRXQxbGsyX0haeUItZm9TZ25lNE00OVFDUkRqLVR3bVUtbUFKR3NUS0laOEg3V3d1dVpocTRiak16YUsyQVE?oc=5","date":"2026-04-06","type":"pipeline","source":"Fierce Pharma","summary":"March M&A surge triggers high expectations for 2026 - Fierce Pharma","headline":"March M&A surge triggers high expectations for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNY3pTT3RIbm9ydFlBblFQY3RBNnZ6Z1lhSGZmMnpjc1FqaHR1UHN4cGNqSmY0YVVQb2JYaXExekpCZjBvNXNuUUpxMzB3a3NPQWM3bTI3VjlUMkpPS1RRYUlCX0o4b3F0NGdJRVYxV19ZX1lKZWlzbWtYQUZhYWVxZjV0MVg4SGhwLXdnNUVsdTRYLVkwbUZOUThCZDl3Q1hUa0Uw?oc=5","date":"2026-03-20","type":"pipeline","source":"Yahoo Finance","summary":"LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions - Yahoo Finance","headline":"LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQkdrOVY4NGNTc3B6b2dINDU4X09PaU1OZjRUM2NHdk43dEM3cVhQb2RQUjBpS19zS0ZuMURXeDNFTDMxbVlteW5uaHYzRlJza3Vta0JjU1YxT0ZrRXFOM3B2aGJycjFldDRSUzRWTV8zR2NJS19RQlA2QjFhaEJvV1lNb0w0ek9mYjVqbEd4QjVWd1ZfcjAtSkg4X0pFVTVpNkhmRGt2dG5ISHhwZGI0RmNIeXVfQQ?oc=5","date":"2026-03-13","type":"pipeline","source":"Bloomberg.com","summary":"Danish Drugmaker Leo Pharma Is Said to Seek Bank Pitches for IPO - Bloomberg.com","headline":"Danish Drugmaker Leo Pharma Is Said to Seek Bank Pitches for IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxORDFMMWFEUGFER1lCUzNRM2o2V3RxendFMy1xWGphOS1weURTM2hzUkU2c0NvUjZkMHAzbS1LNWxmZi00MDJJNVpmdDNHME9xOXo5aE1KMzNjX2NzMnFTLUY3ZzhnRlFBVlMtLW00TjBXRF9ZNUExVU9hTEhjcnJlMmNCSS1nbDZQUXBObEJaMEl1SjhabllRcEZIeS01R2I2Z3RWblJ4UWJpb1BVbW4yQmctcF9fLUJkeDkxWnVnYzBBM0hjdVE1UnZod0pjMFJ2d005bm1QTW4?oc=5","date":"2026-03-05","type":"regulatory","source":"BioSpace","summary":"“It’s GO time”: LEO Pharma launches Direct-to-Consumer campaign to raise awareness of Chronic Hand Eczema - BioSpace","headline":"“It’s GO time”: LEO Pharma launches Direct-to-Consumer campaign to raise awareness of Chronic Hand Eczema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQSXd4NGJMMUF2M2k1dmJMNXY4SmlKNVhPRnlpUHdMdkdtQ2NFSnFNbjhrRnh5am1OeDY4NVA5a0Y3R2I2eTVDZ0hfajJCNHMzNzRLMVZqV3hQT0ZJcHo3c3VQMU1fUm5XVEZocEdnajRmN1FLVEZlM01ESW9Va21NdkZSTi1qSjd4VU5OYQ?oc=5","date":"2026-03-05","type":"regulatory","source":"Medical Marketing and Media","summary":"LEO Pharma launches DTC campaign for Anzupgo to tackle chronic hand eczema misconceptions - Medical Marketing and Media","headline":"LEO Pharma launches DTC campaign for Anzupgo to tackle chronic hand eczema misconceptions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPbFo4Qm9KWHR2dHNScTlENnplU1lMWUJVS1c3NWFiM3ZFM2ZsaHIySnF3eUNDSjF2ODRYenBabTFYU3JGenE0ZldVMF9UYkI5b254MXZvWTFNSlMxQnlBdHlZemJGajdULXQwMmlxNmNaLVlYdUxTRWNXdVV0bEg5MWNVaGEwSFQwbmlRRnU1bmZlUGdTUG55UWhjcXhhUl92WFptbzk4V1Bfc0JwaFMyWlk0SWJGdFpacEV6MXBvZnpWMVphWHRpalIxV1hQVmttYmlCbG5LaXFVNzZuTW9xWg?oc=5","date":"2026-02-18","type":"earnings","source":"Business Wire","summary":"LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin - Business Wire","headline":"LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNRjhBSTN1QUVVQ1lZbzdRQ1RYOXd5RW5NOTNwcEs2RzRlQ3VhdmFDMWRHS1VMUUJFSG0zOFN3ZGo4ZU03anhIZkRmQ1pPSjdxdUExMXRIQ3lTaUQ3MnNZVW9rSDEyOEhlTnMwR3Blb2VfNkFOY1hNeDBfMUxNdG10RktoV24?oc=5","date":"2026-01-23","type":"pipeline","source":"Yahoo Finance","summary":"LEO Pharma Presents Twenty-Three Posters at Maui Derm Hawaii 2026, Demonstrating Continued Commitment to Scientific Innovation in Medical Dermatology - Yahoo Finance","headline":"LEO Pharma Presents Twenty-Three Posters at Maui Derm Hawaii 2026, Demonstrating Continued Commitment to Scientific Inno","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNc0xZUFprMFhJZFl0eG5Vb0V5NzRzUW9odFljZmVRS04tOVFid0MxRXZyLUpNcmVaczU5c1BSREZBeHFycmlFcXNva2JQTldnTU1lYWhLTjU2dXd5dk1lVmVIZm5SaUp5TlFQVmt5WU5fcmswN1liRG9Hc19GcWt6cG5DSlQ4RlVGNXViUnFpWmg3bTd6RjdmYy1WS1RrZnJOWHJsZnlfUmhBODhHR0Q1OEFZZ294elN5Qlc5ZlBlbUZYdEl5?oc=5","date":"2026-01-21","type":"trial","source":"BioSpace","summary":"LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS) - BioSpace","headline":"LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPeUplSDZ2YkdYYTJxRHlIUGhhZHZBXy1fWE9fd0NFcUZFV3dPLVM1RjJvWWRmT0dIRW9yVnFSOW1RR0syeWU3M2ZPTUNhWmp1QTU3R0VIMEJYN0Zpb3VwYnlPczAzMjUtb01nTU93N2djX3hzZkFKOE1zU0MwdXlsQTdSam9yRTE5U3o5Z29tZW50aGNlQ3JxTjBGbDNZSGxoTnZVQWtmWkVJX0Z4am9DcU9HdnNNQl9jTENrelVSbUtYODBZYmVBU1o0YWc?oc=5","date":"2026-01-15","type":"trial","source":"Clinical Trials Arena","summary":"JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases - Clinical Trials Arena","headline":"JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTi1ORDZWZVhFNzdkVzBrdXVEZm1wYkVIaDcxMVBWbjFPS203aFRBNzJxTm5JV0h1b1pycWhWR0xCRFVOWDN6czFXZ3doampoRnV3TG00d0QtRHc2bTBSWGpDenJmZW1DdGhqREZQclFSQTNCQTVFQk5EWng2dGxZLUtjNHdqSGtOR3dGS2VjQUV1eTVkUF9yRXItNWF3eENDLThiYTl5ZHdleFFKeVByMWFCT0kxUlNDZ183OWkybk1yZw?oc=5","date":"2026-01-13","type":"deal","source":"Fierce Pharma","summary":"JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases - Fierce Pharma","headline":"JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9HX1RRT3dBX29iYmxmQmhOMUlROVhjTlNodEpNMDRMV0diSWpmNXZjY1FXUmgzWHFfWVBMa0NTMHB0M0pIcHRDNUdyeHlkdzBaeUR3NzhzSm0tbnI2a3pZMFFBakcxV2VDN3pXSmpHYw?oc=5","date":"2025-12-16","type":"pipeline","source":"medwatch.com","summary":"Leo Pharma taps Amgen executive as new SVP of Global Product Strategy - medwatch.com","headline":"Leo Pharma taps Amgen executive as new SVP of Global Product Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQQzlnQl9kUzN2WFp3VUhwQ3pWeS1qWkU3cVBtbUlicW5nLWxIbWZ1c1pDQnlRM2o1Y05NU3NERG9CUFBmSFFLUkpfZWZWV0E2VHZtdlJYbXoyOF95VU1PSmc4LTl5LVREeUJPNEtwdTU5MFdoZmduMFpWOFNlVUdCOGFxNVlJdEloNWI2d2hnNHRaTkNHd0FJ?oc=5","date":"2025-10-03","type":"pipeline","source":"Dermatology Times","summary":"LEO Pharma Finalizes Acquisition of Spesolimab for GPP - Dermatology Times","headline":"LEO Pharma Finalizes Acquisition of Spesolimab for GPP","sentiment":"neutral"}],"patents":[{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"7700076","type":"Formulation","expiryDate":"2027-09-18","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"10117812","type":"Formulation","expiryDate":"2027-10-18","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"9265725","type":"Formulation","expiryDate":"2027-12-08","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"9211259","type":"Method of Use","expiryDate":"2029-02-28","territory":"US","genericFilings":[]}],"drugCount":67,"phaseCounts":{"marketed":17,"phase_3":31,"phase_2":15,"discontinued":2,"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}